Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France
Open Access
- 22 January 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0245652
Abstract
This study assesses the cost-effectiveness of Technology Lipido-Colloid with Nano Oligo Saccharide Factor (TLC-NOSF) wound dressings versus neutral dressings in the management of diabetic foot ulcers (DFUs) from a French collective perspective. We used a Markov microsimulation cohort model to simulate the DFU monthly progression over the lifetime horizon. Our study employed a mixed method design with model inputs including data from interventional and observational studies, French databases and expert opinion. The demographic characteristics of the simulated population and clinical efficacy were based on the EXPLORER double-blind randomized controlled trial. Health-related quality of life, costs, and resource use inputs were taken from the literature relevant to the French context. The main outcomes included life-years without DFU (LYsw/DFU), quality-adjusted life-years (QALYs), amputations, and lifetime costs. To assess the robustness of the results, sensitivity and subgroup analyses based on the wound duration at treatment initiation were performed. Treatment with the TLC-NOSF dressing led to total cost savings per patient of EUR 35,489, associated with gains of 0.50 LYw/DFUand 0.16 QALY. TLC-NOSF dressings were established as the dominant strategy in the base case and all sensitivity analyses. Furthermore, the model revealed that, for every 100 patients treated with TLC-NOSF dressings, two amputations could be avoided. According to the subgroup analysis results, the sooner the TLC-NOSF treatment was initiated, the better were the outcomes, with the highest benefits for ulcers with a duration of two months or less (+0.65 LYw/DFU, +0.23 QALY, and cost savings of EUR 55,710). The results from the French perspective are consistent with the ones from the German and British perspectives. TLC-NOSF dressings are cost-saving compared to neutral dressings, leading to an increase in patients’ health benefits and a decrease in the associated treatment costs. These results can thus be used to guide healthcare decisionmakers. The potential savings could represent EUR 3,345 per treated patient per year and even reach EUR 4,771 when TLC-NOSF dressings are used as first line treatment. The EXPLORER trial is registered with ClinicalTrials.gov, number NCT01717183.Keywords
Funding Information
- Urgo Medical
This publication has 31 references indexed in Scilit:
- Improving major amputation rates in the multicomplex diabetic foot patient: focus on the severity of peripheral arterial diseaseTherapeutic Advances in Endocrinology and Metabolism, 2013
- Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews2013
- 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot InfectionsaClinical Infectious Diseases, 2012
- A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetesDiabetes/Metabolism Research and Reviews, 2012
- Economic evaluation of Vacuum Assisted Closure® Therapy for the treatment of diabetic foot ulcers in FranceInternational Wound Journal, 2010
- An Evidence-Based Model Comparing the Cost-effectiveness of Platelet-Rich Plasma Gel to Alternative Therapies for Patients with Nonhealing Diabetic Foot UlcersAdvances in Skin & Wound Care, 2008
- Evaluation of the nano‐oligosaccharide factor lipido‐colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trialInternational Wound Journal, 2008
- Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcersInternational Journal of Technology Assessment in Health Care, 2008
- Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatmentsDiabetes & Metabolism, 2004
- Markov Models in Medical Decision MakingMedical Decision Making, 1993